Drugs.com - Clinical Trials

Eneboparatide Met Primary Endpoint of Normalising Serum Calcium in Adults with Hypoparathyroidism at 24 weeks in CALYPSO Phase III Trial

March 17, 2025 -- High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical significance in adults with...

Mar 17, 2025 - 23:19
 0
Eneboparatide Met Primary Endpoint of Normalising Serum Calcium in Adults with Hypoparathyroidism at 24 weeks in CALYPSO Phase III Trial
March 17, 2025 -- High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical significance in adults with...
Read More

Tags:

Previous Article

DOGE order leads to journal cancellations by U.S. agricultural library

Next Article

Taking a look at tariffs with S&P Global Market Intelligence Economist Paul Bingham

Related Posts

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data for Isaralgagene Civaparvovec in Fabry Disease

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR ...

Feb 9, 2025  0

BlueRock Therapeutics Receives FDA Fast Track Designation for OpCT-001 for the Treatment of Primary Photoreceptor Diseases

BlueRock Therapeutics Receives FDA Fast Track Designati...

Mar 1, 2025  0

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

Kura Oncology and Kyowa Kirin Announce Positive Ziftome...

Feb 9, 2025  0